Eli Lilly and Company (LLY)vsCharming Medical Limited Class A Ordinary Shares (MCTA)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
MCTA
Charming Medical Limited Class A Ordinary Shares
$29.36
0.00%
HEALTHCARE · Cap: $504.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1332121% more annual revenue ($72.25B vs $5.42M). LLY leads profitability with a 35.0% profit margin vs 12.1%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
MCTA
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Earnings expanding 81.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MCTA
The strongest argument for MCTA centers on EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : MCTA
The primary concerns for MCTA are Altman Z-Score, Market Cap, Return on Equity. A P/E of 419.4x leaves little room for execution misses. Debt-to-equity of 23.57 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while MCTA is a declining play — different risk/reward profiles.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 27/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Charming Medical Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?